Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.92
-0.3800-0.53%
Post-market: 70.920.00000.00%19:30 EDT
Volume:3.24M
Turnover:229.27M
Market Cap:3.98B
PE:6.39
High:71.04
Open:70.96
Low:69.71
Close:71.30
52wk High:74.59
52wk Low:59.47
Shares:56.10M
Float Shares:56.10M
Volume Ratio:6.19
T/O Rate:5.78%
Dividend:0.80
Dividend Rate:1.13%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.42
PE(LYR):23.18

Loading ...

AlzeCure Pharma to Present at Redeye Neurology Day

Reuters
·
Oct 07

NIB Holdings Seeks ASX Quotation for New Dividend Plan Shares

TIPRANKS
·
Oct 07

Will Drug Approvals Change Merck (MRK) Narrative

Simply Wall St.
·
Oct 07

Perrigo Co. PLC Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Oct 07

AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says

MT Newswires Live
·
Oct 07

SMAIO Signs Sales Agency Agreement with DePuy Synthes for US Market

Reuters
·
Oct 07

Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone

TIPRANKS
·
Oct 07

Smaio - Signs Sales Agency Agreement with Depuy Synthes for US Market

THOMSON REUTERS
·
Oct 06

General Medicine Raises $120 Mln to Build the Healthcare Store

Reuters
·
Oct 06

Johnson & Johnson's Innovative Medicines Momentum Offsets MedTech Headwinds, RBC Capital Markets Says

MT Newswires Live
·
Oct 06

General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company

THOMSON REUTERS
·
Oct 06

European Shares Gain as Genmab Jumps, Bond Yields Retreat

Reuters
·
Oct 06

LIVE Markets-a Health Boost for the STOXX

Reuters
·
Oct 06

Genmab at 3-Year High After Blood Cancer Drug Combination Study Results

Reuters
·
Oct 06

Tech Coast Angels Reports Profitable Atraverse Medical Exit After Johnson & Johnson Acquisition, Citing 70%+ IRR

Reuters
·
Oct 06

L'Oreal Explores Unloading Chemical-Related Liabilities, WSJ Reports

Reuters
·
Oct 06

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
Oct 06

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
Oct 06